Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.52 |
| ▸ | PPARD | Q03181 | 14/20 | 0.52 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813025 | 0.94 | PPARA (0.53) | PPARAPPARDPPARG | |
| SCHEMBL4808451 | 0.93 | PPARA (0.59) | PPARAPPARDPPARG | |
| SCHEMBL5419536 | 0.92 | PPARD (0.42) | PPARAPPARDPPARGCACNA1GKCNH2 | |
| SCHEMBL4808817 | 0.92 | PPARD (0.56) | PPARAPPARDPPARG | |
| SCHEMBL4812093 | 0.88 | PPARA (0.49) | PPARAPPARDPPARGCACNA1GKCNH2 | |
| SCHEMBL4810762 | 0.88 | PPARA (0.61) | PPARAPPARDPPARG | |
| SCHEMBL4808137 | 0.87 | PPARA (0.57) | PPARAPPARDPPARG | |
| SCHEMBL2403715 | 0.87 | PPARA (0.57) | PPARAPPARDPPARG | |
| SCHEMBL4809754 | 0.86 | PPARD (0.59) | PPARAPPARDPPARG | |
| SCHEMBL4809132 | 0.86 | PPARA (0.48) | PPARAPPARDUSP2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449468-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-09-27 | — | — | US | disclosed |
| US-7229998-B2 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | BANKER PIERETTE | 2007-03-29 | — | — | US | disclosed |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072871-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | PPARD, PPARG, PPARA | PPARA 3/4885PPARD 1/4885PPARG 2/4885 |
| US-20070225294-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GPR119, PPARA, PPARG | PPARA 2/4885PPARD 4/4885PPARG 3/4885 |
| US-20040072838-A1 | Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors | PPARA, PPARG, PPARD | PPARA 1/4885PPARD 3/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.